The mechanism of action (MOA) of the next generation of protein-directed therapeutics are complex and require a new generation of biomarker assays that accurately reflect this complexity. Antibody-drug conjugates (ADCs), multi-specifics, and immunotherapy combos increasingly depend on spatial scoring and multiplex detection to predict treatment outcomes.
Spatial scoring and multiplex detection require AI-powered solutions to accelerate panel optimization, biomarker discovery, and clinical deployment.
In this talk, the speaker, Dr. Jason Reeves, will share case studies on how AI-powered spatial biomarkers and diagnostics have the potential to transform drug development and clinical treatment decisions.
